As part of its Tribute Awards, the Muscular Dystrophy Association (MDA) will honor Alan Pestronk, MD, co-director of the MDA & ALS Care Center at Washington University School of Medicine. The Tribute Awards recognizes those “who have been tireless in their efforts” to support members of the neuromuscular disease…
I remember those days when it was hard to get out of the house with our newborns. Two weeks after our daughter was born, my husband, Todd, and I celebrated Valentine’s Day with dinner at home. Todd bought jewelry for both Sara and me. Life has patterns and seasons, and…
NeuroSense Therapeutics has joined EverythingALS’s open innovation consortium to accelerate the development of treatments for amyotrophic lateral sclerosis (ALS). NeuroSense will provide financial support for ongoing research projects from the patient-focused nonprofit organization, such as those that seek to identify biological and digital biomarkers to help detect and monitor ALS.
NeuroSense Therapeutics and NeuraLight are collaborating to identify digital biomarkers, particularly those drawn from facial videos, that would help in detecting and monitoring amyotrophic lateral sclerosis (ALS) and other neurological diseases. Called occulometric biomarkers, they are derived from videos of patients’ faces captured on a webcam and analyzed…
There I was, just living each day and minding my own business. I was following all the guidelines from the U.S. Centers for Disease Control and Prevention and wearing a mask everywhere I went, when all of a sudden, BAM! The COVID-19 virus found me. What followed were…
Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada, its developer, Amylyx Pharmaceuticals, announced. Its market availability comes about 1.5 months after the therapy was conditionally approved by Health Canada for this neurodegenerative disease. The regulatory decision was based on…
TDP-43 protein abnormalities characteristic of most amyotrophic lateral sclerosis (ALS) cases contribute to the loss of motor neurons mostly by limiting the function of a protein called stathmin-2 (STMN2), a study reported. Results indicate that boosting STMN2 levels may be a useful approach in treating ALS, according to its…
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential treatments for amyotrophic lateral sclerosis (ALS). The non-dilutive funds became available following the company’s acquisition of Alpha-5 Integrin, the preclinical biotech company that originally developed the experimental antibodies for…
Music had been a source of connection and mild contention early in my relationship with my husband, Todd, but it hadn’t been much of either since Todd became paralyzed due to ALS. Our first date was to an Alison Krauss & Union Station concert. Todd was new to Milwaukee…
Amylyx Pharmaceuticals has partnered with Sunnybrook Research Institute (SRI) to find new therapeutic candidates for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Under terms of the two-year sponsored research agreement, SRI will work to identify potential therapeutics that potently and specifically inhibit Bax and Bak, two proteins…
Get regular updates to your inbox.